Septerna: Specialist in oral GPCR drugs impresses with strong pipeline
Reading Time: 3 minutes
SEP-479 targets the potential billion-dollar market for hypoparathyroidism and aims to replace current injectable standard therapies. With Novo Nordisk, the Native Complex Platform serves as the basis for research on the next generation of weight loss pills. Raymond James upgrades to 53 USD (Strong Buy) based on preclinical data. Approximately 552 million USD in liquid assets are projected to secure financing through 2029. Septerna (SEPN) is a biotechnology company in the clinical development phase focused on oral, low-molecular-weight...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
